Anthem Biosciences IPO: Rs 3,395 crore IPO to open on July 14
About Anthem Biosciences IPO
The IPO is an Offer for Sale (OFS) and comprises stake sale aggregating up to Rs 350 crores each by Ganesh Sambasivam and K Ravindra Chandrappa who are promoter selling shareholders. Up to Rs 1,325 crores will be offloaded by Viridity Tone LLP and up to Rs 320 crores by Portsmouth Technologies LLC (Investor Selling Shareholders).
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Free P2,000 GCash eGift
UnionBank Credit Card
Apply Now
Undo
It also includes stake sales of Rs 320 crores each by Malay J Barua, Rupesh N Kinekar and Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan.
About Anthem Biosciences
Anthem's business comprises Contract Research, Development and Manufacturing Organization (CRDMO) services and the manufacture and sale of specialty ingredients. It offers a comprehensive, integrated and highly customizable range of CRDMO services across the New Chemical Entity (NCE) and New Biological Entity (NBE) lifecycles.
The company claims to have a strong presence across various modalities, such as RNAi, ADC, peptides, lipids and oligonucleotides, and manufacturing techniques, such as flow chemistry, enzymatic processes, biocatalysis and fermentation, offering a broad range of technology capabilities for drug development.
It also manufactures and sells complex specialized fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
Live Events
Ajay Bhardwaj (Chairman, MD & CEO), Ganesh Sambasivam (Whole-time Director and Chief Scientific Officer), K Ravindra Chandrappa (Whole-time Director and Chief Operating Officer) and Ishaan Bhardwaj (Vice President) are the Promoters of the company.
The company, which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity of 270 kL and fermentation capacity of 142 kL, as of March 31, 2025.
According to the RHP, the company is in the process of expanding its custom synthesis capacity at Unit II (Harohalli) by 130 kL as well as expanding its custom synthesis capacity by 25kL and fermentation capacity by 40kL by constructing Unit III (Neoanthem Lifesciences Private Limited, wholly-owned Subsidiary), both expected to be fully operational by the first half of Fiscal 2026.
Post-expansion activities, the aggregate annual custom synthesis capacity and fermentation capacity is expected to increase to 425 kL and 182 kL, respectively. The fermentation capacity of 182 kL is expected to be more than six times the capacity of the second largest player in this industry, according to the F&S Report.
Anthem Biosciences financials
Its revenue from operations increased by 30% to Rs 1,844 crores in FY25 from Rs 1,419 crores in FY24. The PAT for the year ended March 31, 2025 was Rs 451 crores, a jump of 22.86% over FY24.
Sai Life Sciences Limited,
Syngene International Limited
,
Cohance Lifesciences Limited
, (Formerly Suven Pharmaceuticals) and Divi's Laboratories Limited are the listed peers of Anthem Biosciences, as per its RHP.
Anthem Biosciences lead managers
The Book Running Lead Managers to the offer are
JM Financial Limited
, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited.
The equity shares are proposed to be listed on BSE and NSE.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
30 minutes ago
- Time of India
India-US trade deal: Donald Trump administration may cut tariff to below 20%; putting India in favourable position against other countries
This is an AI image. United States is working toward an interim trade agreement with India that could reduce proposed tariffs to below 20%, giving the country a more favorable position compared to other countries in the region. Unlike many nations, India is not expected to receive a formal tariff hike notice this week, and the agreement may be announced through an official statement, Bloomberg reported, quoting sources. The proposed interim trade deal between the two nations would allow both the sides to continue negotiations, giving India time to address unresolved issues before a broader agreement expected later this year, the source added. India, US near trade deal. What happens next if New Delhi joins Trump's shortlist? The planned agreement is likely to set a baseline tariff of under 20%, down from the 26% initially proposed, with provisions to allow further adjustments as part of a final pact. However, the exact timeline for the interim deal remains uncertain. If finalised, India would likely join a select group of nations that have reached trade arrangements with the Trump administration. In contrast, several other countries were hit with surprise tariff hikes of up to 50% this week, ahead of the August 1 deadline. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 기미, 레이저말고 이렇게 해보세요 에스테틱최원장 Undo India is pushing for a more favourable deal than the one signed with Vietnam, which included 20% tariffs. Vietnam, caught off guard by the high rate, is now seeking a revision. So far, only the UK has officially signed trade deals with the Trump administration. Earlier on Thursday, Trump told NBC News that he is considering imposing blanket tariffs of 15% to 20% on most trading partners who haven't yet received specific rates. Currently, the baseline tariff for most US trade partners stands at 10%. For Asian countries, announced rates so far include 20% for Vietnam and the Philippines, and as high as 40% for Laos and Myanmar. Despite being among the earliest to initiate trade discussions this year, India-US relations have shown recent tensions. While Trump indicates an imminent agreement, he has also suggested additional tariffs regarding India's BRICS membership. An Indian negotiation team is expected to visit Washington soon to push forward trade talks. India has already made its final offer to the Trump administration and outlined its non-negotiable positions. The key sticking points remain, including the US demand for India to allow genetically modified (GM) crops, something New Delhi has firmly opposed, citing concerns for farmers, while the other unresolved issues include agricultural non-tariff barriers and regulatory hurdles in the pharmaceutical sector, the source added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
New Indian Express
31 minutes ago
- New Indian Express
GST notices based on UPI data: Tax department
BENGALURU: Following reports of notices issued to small traders by the Commercial Tax Department, the state government clarified on Friday that the action was based on data collected from Unified Payments Interface (UPI) service providers to ensure compliance with Goods and Services Tax (GST) laws. Under the GST Act, in force since July 1, 2017, suppliers with an annual turnover exceeding Rs 40 lakh (for goods) or Rs 20 lakh (for services) are required to register for GST. This turnover includes both taxable and exempt goods and services, although tax is applicable only on taxable items. The department said while essential items like bread are exempt from GST, packaged snacks attract a 5% tax. It said UPI-based transaction data from 2021–22 to 2024–25 showed that many traders had received over Rs 40 lakh via UPI alone, excluding cash and other payment methods, indicating even higher total turnover. Based on this data, the department issued notices to traders. ENS
United News of India
41 minutes ago
- United News of India
Selling SBI shares worth Rs 25000 cr part of privatisation: BEFI
Thiruvananthapuram, July 12 (UNI) Bank Employees Federation of India has alleged that the Centre's move to sell shares of State Bank of India (SBI) worth Rs 25,000 crore SBI) is an open attempt to privatize the bank in a phased manner sacrificing national interests. "In 2017, the bank had sold 522 million shares. This reduced the government's stake in the bank to 56.92 percent. Now, with the completion of the targeted share sale, the government's stake will diminish below 55 percent," BEFI vice president Saji Varghese said. "The sale of shares through qualified institutional placement has been reported by national media," he added. "Despite the vacancies of about one lakh employees and officers, the outsourcing of jobs and the deployment of daily wage workers without making them permanent is a prelude to privatization... After the budget presentation, the Union Finance Minister had announced that government would sell shares of public sector banks including SBI. Other public sector banks are also preparing for share sale" he said. The privatization of the country's largest public sector bank, SBI, will have far-reaching consequences. Public sector banks serve as a protective shield for the Indian economy. It is this protective shield that is being undermined through bank privatization, he stated. "As banks come under the control of corporates, services for the common people will get affected and services will be limited to the elite class," he added. The SBI plans to support loan growth, strengthen its balance sheet and meet regulatory requirements. It's also the first time since 2017 that the lender, majority owned by the government, tapped the equity market. UNI DS AAB RKM
